Key result
Pravastatin appears to mitigate excess all-cause mortality in elderly patients with high FIB-4 scores.
Why the study?
Does pravastatin reduce all-cause mortality and cardiovascular endpoints in elderly patients at risk of liver fibrosis?
RCT (n=5,804)
Double-blind
randomized
Does pravastatin reduce all-cause mortality and cardiovascular endpoints in elderly patients at risk of liver fibrosis?
Answers are grounded in this paper and cite their sources.
In an elderly population at increased cardiovascular risk, pravastatin may mitigate the increased risk of all-cause mortality associated with a high risk of liver fibrosis.
Background & Aims: Metabolic dysfunction-associated steatotic liver disease (MASLD), especially the progressive stages accompanied by liver fibrosis, are associated with liver-related and cardiovascular (CV) complications in middle-aged cohorts. We evaluated whether liver fibrosis is associated with increased mortality and cause-specific endpoints in an elderly population, and whether statin treatment could reduce these risks. Methods: PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) was a double-blind randomized clinical trial comparing pravastatin to placebo in an elderly Caucasian population of 5,804 patients (>70 years of age) at increased risk of CV disease. Endpoints were composite and single (CV) endpoints and all-cause mortality. The Fibrosis-4 index (FIB-4) score was classified as: low risk of liver fibrosis (FIB-4 <2.0), indeterminate risk (2.0≤ FIB-4 ≤2.66), and high risk (FIB-4 ≥2.67). Time-to-event data were analyzed using the Cox proportional hazards model. High FIB-4 classifications were not significantly associated with major adverse cardiovascular events (MACE) or other endpoints in either arms. Conclusions: A high FIB-4 classification is associated with increased all-cause mortality in the elderly, although pravastatin appears to mitigate this increased risk. Clinical Trials registration: The study is registered at www.isrctn.com/(ISRCTN40976937). Impact and implications: The progressive stages of MASLD (liver fibrosis) are associated with liver-related and CV complications in middle-aged cohorts (∼55 years of age). The impact of liver fibrosis in elderly populations is less well studied. In addition, the use of statins has long been debated, but evidence appears to point to a beneficial effect in populations with MASLD. However, data from prospective trials remain limited. Our findings indicate a potential survival benefit associated with pravastatin use in the elderly (>70 years of age) with an indication of liver fibrosis.
No takes yet. Share an insight, caveat, or question.
Jong et al. (2025) conducted an RCT in Increased risk of cardiovascular disease and liver fibrosis (n=5,804). Pravastatin vs. Placebo was evaluated on Composite and single (CV) endpoints and all-cause mortality (p=0.049). Pravastatin appears to mitigate the increased risk of all-cause mortality associated with a high FIB-4 classification (liver fibrosis) in elderly patients.
Synapse has enriched 10 related papers. Consider them for comparative context: